Showing results (71-80 of 135) with videos related to
Sort By:
Pageof 14
Statistics in Medicine|October 23, 2023
Minimization in randomized clinical trialsElisabeth Coart, Perrine Bamps, Emmanuel Quinaux, et al.Cancers|November 13, 2021
Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping ReviewRenata Duchnowska, Everardo D Saad, Małgorzata Banaszek, et al.Journal of Clinical Epidemiology|April 13, 2015
Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancerOriana Ciani, Marc Buyse, Ruth Garside, et al.Journal of the National Cancer Institute|April 19, 2007
Potential drug interactions and duplicate prescriptions among cancer patientsRachel P Riechelmann, Ian F Tannock, Lisa Wang, et al.Journal of Clinical Epidemiology|March 28, 2021
The Net Benefit of a treatment should take the correlation between benefits and harms into accountMarc Buyse, Everardo D Saad, Julien Peron, et al.Investigational New Drugs|May 4, 2004
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancerPaulo M Hoff, Everardo D Saad, Richard Pazdur, et al.International Braz J Urol : Official Journal of the Brazilian Society of Urology|January 24, 2015
Brazilian abstracts presented at the American Urological Association annual meetings: contribution, publication rates, and comparison with oncology abstractsMarco A Arap, Rodolfo Borges dos Reis, Fábio César Miranda Torricelli, et al.Clinical Colorectal Cancer|December 14, 2011
Literature review and practical aspects on the management of oxaliplatin-associated toxicityPaulo M Hoff, Everardo D Saad, Frederico Costa, et al.Atherosclerosis|February 24, 2015
Pericardial fat is associated with all-cause mortality but not incident CVD: the Rancho Bernardo StudyBritta A Larsen, Gail A Laughlin, Sarah D Saad, et al.American Journal of Clinical Oncology|October 24, 2002
Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancerEverardo D Saad, Eric H Kraut, Paulo M Hoff, et al.Pageof 14